Extension of Time to File SOU

PTO Form 1581 (Rev 9/2005)

OMB No. 0651-0054 (Exp. 10/31/2017)

---

PTO Form 1581 (Rev 9/2005)

OMB No. 0651-0054 (Exp. 10/31/2017)

SOU Extension Request
(15 U.S.C. Section 1051(d))

To the Commissioner for Trademarks:

MARK: AILERON
SERIAL NUMBER: 85566635

The applicant, Aileron Therapeutics, Inc., having an address of
      281 Albany Street
      Cambridge, Massachusetts 02139
      United States
requests a six-month extension of time to file the Statement of Use under 37 C.F.R. Section 2.89 in this application.    The Notice of Allowance mailing date was 09/25/2012.

For International Class 005:
Current identification: pharmaceutical compositions, namely, preparations for the treatment of obesity, cancer, diabetes, neurodegenerative disorders, cardiovascular disease and disorders, metabolic syndrome, autoimmune disorders, central nervous system diseases and disorders, neurological disorders, urological disorders, gastrointestinal disorders, musculoskeletal disorders, allergies, hypertension, erectile dysfunction, sexual dysfunction, stroke, migraines, pain, inflammation and inflammatory diseases, respiratory and infectious diseases, immunological disorders, anxiety, depression, neuropsychiatric disorders including both psychotic and non-psychotic conditions, and substance abuse disorders, including both abuse and dependence, disorders of blood cell production, organ transplant rejection, endocrinologic disorders, and bacterial, viral and fungal diseases; diagnostic products, namely, medical diagnostic reagents, diagnostic reagents for clinical or medical laboratory use; biological reagents for medical purposes in the field of molecular biology; reagents for use in biological processing for medical purposes

This filing does NOT cover the following goods/services listed in either the application or Notice of Allowance or as subsequently modified; these goods/services are either being permanently deleted or included in a separately filed Statement of Use with a Request to Divide: obesity, diabetes, neurodegenerative disorders, cardiovascular disease and disorders, metabolic syndrome, autoimmune disorders, central nervous system diseases and disorders, neurological disorders, urological disorders, gastrointestinal disorders, musculoskeletal disorders, allergies, hypertension, erectile dysfunction, sexual dysfunction, stroke, migraines, pain, inflammation and inflammatory diseases, respiratory and infectious diseases, immunological disorders, anxiety, depression, neuropsychiatric disorders including both psychotic and non-psychotic conditions, and substance abuse disorders, including both abuse and dependence, disorders of blood cell production, organ transplant rejection, endocrinologic disorders, and bacterial, viral and fungal diseases; diagnostic products, namely, medical diagnostic reagents, diagnostic reagents for clinical or medical laboratory use; biological reagents for medical purposes in the field of molecular biology; reagents for use in biological processing for medical purposes

For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this specific class: pharmaceutical compositions, namely, preparations for the treatment of cancer

This is the fifth extension request. The applicant has made the following ongoing efforts to use the mark in commerce on or in connection with each of those goods/services covered by the extension request: Applicant believes it has made valid use of the mark in commerce, and is in the process of concurrently filing a Statement of Use (SOU), but if the PTO finds the SOU to be fatally defective, Applicant will need additional time to file a new SOU.

A Statement of Use has already been submitted or is being submitted along with the Extension request as evidence that applicant believes that it has made valid use of the mark in commerce.   If the USPTO finds the Statement of Use to be fatally defective, the applicant requests additional time to file an amended or substitute Statement of Use.



A fee payment in the amount of $150 will be submitted with the form, representing payment for 1 class.


Declaration

DECLARATION: The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. Section 1001, and that such willful false statements and the like may jeopardize the validity of the application or submission or any registration resulting therefrom, declares that all statements made of his/her own knowledge are true and that all statements made on information and belief are believed to be true.


Signature: /Allen Annis, Ph.D./      Date Signed: 03/23/2015
Signatory's Name: Allen Annis, Ph.D.
Signatory's Position: Vice President, Biophysical and Analytical Technologies
Signatory's Phone: Not Required

RAM Sale Number: 85566635
RAM Accounting Date: 03/24/2015

Serial Number: 85566635
Internet Transmission Date: Mon Mar 23 14:17:05 EDT 2015
TEAS Stamp: USPTO/ESU-XX.XX.XXX.XXX-2015032314170562
2040-85566635-53019e8f1d29027cb79976dba8
2b73b8cd5892c94e814728ed4951b9cfb9426e1a
8-DA-542-20150319215952836629